Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRF-1101 (pentosan polysulfate sodium) in sickle cell disease
2008-003573-41Phase 2Terminated
- Sponsor
- TRF Pharma
- Start
- Jul 2008
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing TRF-1101 with Placebo (2 arms). Primary endpoints: Safety and tolerability of pentosan polysulfate sodium, Pharmacodynamic activity of pentosan polysulfate sodium on microvascular blood flow and 3 more. Started Jul 2008; status: terminated.
02
Drugs
pentosan polysulfate sodium
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2008-003573-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003573-41.